Literature DB >> 10690506

Modulation of molecular targets to enhance radiation.

P M Harari, S M Huang.   

Abstract

Mesh：

Substances：

Year:  2000        PMID： 10690506

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


× No keyword cloud information.
  12 in total

1.  Curcumin targets FOLFOX-surviving colon cancer cells via inhibition of EGFRs and IGF-1R.

Authors:  Bhaumik B Patel; Deepshika Gupta; Althea A Elliott; Vivek Sengupta; Yingjie Yu; Adhip P N Majumdar
Journal:  Anticancer Res       Date:  2010-02       Impact factor: 2.480

2.  Curcumin enhances dasatinib-induced inhibition of growth and transformation of colon cancer cells.

Authors:  Jyoti Nautiyal; Sanjeev Banerjee; Shailender S Kanwar; Yingjie Yu; Bhaumik B Patel; Fazlul H Sarkar; Adhip P N Majumdar
Journal:  Int J Cancer       Date:  2011-02-15       Impact factor: 7.396

3.  Elimination of Colon Cancer Stem-Like Cells by the Combination of Curcumin and FOLFOX.

Authors:  Yingjie Yu; Shailender S Kanwar; Bhaumik B Patel; Jyoti Nautiyal; Fazlul H Sarkar; Adhip Pn Majumdar
Journal:  Transl Oncol       Date:  2009-12       Impact factor: 4.243

4.  The combination of epidermal growth factor receptor inhibitors with gemcitabine and radiation in pancreatic cancer.

Authors:  Meredith A Morgan; Leslie A Parsels; Laura E Kollar; Daniel P Normolle; Jonathan Maybaum; Theodore S Lawrence
Journal:  Clin Cancer Res       Date:  2008-08-15       Impact factor: 12.531

5.  Phase I trial of erlotinib-based multimodality therapy for inoperable stage III non-small cell lung cancer.

Authors:  Nicholas W Choong; Ann M Mauer; Daniel J Haraf; Eric Lester; Philip C Hoffman; Mark Kozloff; Shang Lin; Janet E Dancey; Livia Szeto; Tatyana Grushko; Olufunmilayo I Olopade; Ravi Salgia; Everett E Vokes
Journal:  J Thorac Oncol       Date:  2008-09       Impact factor: 15.609

6.  Modelling the correlation between EGFr expression and tumour cell radiosensitivity, and combined treatments of radiation and monoclonal antibody EGFr inhibitors.

Authors:  Piernicola Pedicini; Rocchina Caivano; Barbara Alicia Jereczek-Fossa; Lidia Strigari; Barbara Vischioni; Daniela Alterio; Marta Cremonesi; Francesca Botta; Antonio Nappi; Giuseppina Improta; Giovanni Storto; Marcello Benassi; Roberto Orecchia
Journal:  Theor Biol Med Model       Date:  2012-06-19       Impact factor: 2.432

Review 7.  Radiotherapy and "new" drugs-new side effects?

Authors:  Maximilian Niyazi; Cornelius Maihoefer; Mechthild Krause; Claus Rödel; Wilfried Budach; Claus Belka
Journal:  Radiat Oncol       Date:  2011-12-21       Impact factor: 3.481

8.  Randomized phase II--study evaluating EGFR targeting therapy with cetuximab in combination with radiotherapy and chemotherapy for patients with locally advanced pancreatic cancer--PARC: study protocol [ISRCTN56652283].

Authors:  R Krempien; M W Muenter; P E Huber; S Nill; H Friess; C Timke; B Didinger; P Buechler; S Heeger; K K Herfarth; A Abdollahi; M W Buchler; J Debus
Journal:  BMC Cancer       Date:  2005-10-11       Impact factor: 4.430

9.  Therapeutic approaches to target cancer stem cells.

Authors:  Arlhee Diaz; Kalet Leon
Journal:  Cancers (Basel)       Date:  2011-08-15       Impact factor: 6.639

10.  Correlation between expression of epidermal growth factor receptor and adverse reactions after chemotherapy of advanced non-small-cell lung cancer.

Authors:  Zerui Hao; Chunyan Tian; Futang Yang; Jihong Zhang
Journal:  Pak J Med Sci       Date:  2015 Sep-Oct       Impact factor: 1.088
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.